N-(2-羟基苄基)-3-氨基吡啶 | 13199-80-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-羟基苄基)-3-氨基吡啶
• 英文名称: N-(2-hydroxybenzyl)-3-aminopyridine
• 英文别名: 2-(pyridin-3-ylamino-methyl)-phenol；N-(pyridin-3-yl)-N-(2-hydroxybenzyl)amine；N-(3-pyridyl)-N-(2-hydroxybenzyl)amine；2-[(Pyridin-3-ylamino)methyl]phenol
• CAS: 13199-80-9
• 化学式: C₁₂H₁₂N₂O
• mdl: MFCD00023559
• 分子量: 200.24
• InChiKey: RNLPSIGSCNHXKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 N-(2-羟基苄基)-3-氨基吡啶 以 甲醇 、 水 为溶剂， 以63%的产率得到3,4-dihydro-3-pyridin-3-yl-2H-benz[e]-1,3-oxazine
  参考文献：
  名称：

  Synthesis and Biological Activity of Some 3-Aryl-3,4-dihydro-2H-benz[e]- 1,3-oxazines/6-bromo-3-aryl-3,4-dihydro-2H-benz[e]-1,3-oxazines

  摘要：

  N-(2-羟基)-苄基芳胺(1)在甲醇中与甲醛进行环化反应，在65-68°C下0.5-1.0小时内，可以高产率地得到几乎纯的3-芳基-3,4-二氢-2H-苯并[e]-1,3-恶嗪/6-溴-3-芳基-3,4-二氢-2H-苯并[e]-1,1-恶嗪(2)。这些化合物随后被用于针对革兰氏阳性细菌（金黄色葡萄球菌，MTCC 96）和革兰氏阴性细菌（大肠杆菌，MTCC 739）的抗菌活性研究。为了评估抗真菌活性，使用的真菌为白色念珠菌。所有化合物的最低抑制浓度是通过微量肉汤稀释法确定的。

  DOI：

  10.14233/ajchem.2013.14091
• 作为产物：
  描述：

  N-salicylidene-3-aminopyridine 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 N-(2-羟基苄基)-3-氨基吡啶
  参考文献：
  名称：

  Synthesis and Biological Activity of Some 3-Aryl-3,4-dihydro-2H-benz[e]- 1,3-oxazines/6-bromo-3-aryl-3,4-dihydro-2H-benz[e]-1,3-oxazines

  摘要：

  N-(2-羟基)-苄基芳胺(1)在甲醇中与甲醛进行环化反应，在65-68°C下0.5-1.0小时内，可以高产率地得到几乎纯的3-芳基-3,4-二氢-2H-苯并[e]-1,3-恶嗪/6-溴-3-芳基-3,4-二氢-2H-苯并[e]-1,1-恶嗪(2)。这些化合物随后被用于针对革兰氏阳性细菌（金黄色葡萄球菌，MTCC 96）和革兰氏阴性细菌（大肠杆菌，MTCC 739）的抗菌活性研究。为了评估抗真菌活性，使用的真菌为白色念珠菌。所有化合物的最低抑制浓度是通过微量肉汤稀释法确定的。

  DOI：

  10.14233/ajchem.2013.14091

文献信息

• A Quick Route for the Synthesis of 3-Aryl-3,4-dihydro-2H-benz[e]-1,3-oxazin-2-ones
  作者：Davender Kumar Shukla、Manju Rani、Arif Ali Khan

  DOI：10.14233/ajchem.2013.14053

  日期：——

  N-(2-Hydroxy)-benzyl-arylamines (1) gave substantially pure 3-aryl-3,4-dihydro-2H-benz[e]-1,3-oxazin-2-one 2 on cyclization with carbonyldiimidazole in DMSO in 20-30 min at 20-25 ºC in excellent yields.

  N-(2-羟基)-苄基-芳香胺（1）在20-25 ºC的DMSO中与碳酰二咪唑环化，20-30分钟后获得了3-芳基-3,4-二氢-2H-benz[e]-1,3-噁唑啉-2-酮（2），产率非常高。
• Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
  申请人：Cytovia, Inc.

  公开号：US20030078292A1

  公开（公告）日：2003-04-24

  The present invention is directed to gambogic acid, analogs and derivatives thereof, represented by the general Formulae I-III: 1 wherein R 1 -R 5 are defined herein. The present invention also relates to the discovery that compounds having Formula I-III are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled cell growth and spread of abnormal cells occurs.

  本发明涉及以通式I-III所表示的甘黄酸及其类似物和衍生物，其中R1-R5在此定义。本发明还涉及发现具有I-III式的化合物是caspase激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导细胞死亡，在各种临床病情中，不受控制的细胞生长和异常细胞的扩散。
• Histone demethylase inhibitors
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US10179769B2

  公开（公告）日：2019-01-15

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本发明提供了取代的脒基吡啶或脒基哒嗪衍生物化合物以及包含上述化合物的药物组合物。所述化合物和组合物可用于抑制组蛋白去甲基化酶。此外，所述化合物和组合物还可用于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等。
• FUSED OXAZEPINES AS INHIBITORS OF PEROXIREDOXINS
  申请人：Centro Atlántico del Medicamento, SA

  公开号：EP4177246A1

  公开（公告）日：2023-05-10

  Novel quinone-fused oxazepines compounds that inhibit peroxiredoxins, pharmaceutical compositions comprising such compounds, are disclosed. Additionally, methods of treating or alleviating conditions associated with elevated peroxiredoxins levels, and in particular cancer, are also disclosed.

  本发明揭示了一种新型的苯醌融合噁嗪酮化合物，这些化合物能够抑制过氧化物酶，并且包含此类化合物的药物组合物。此外，本发明还揭示了治疗或缓解与过氧化物酶水平升高相关联的疾病的方法，特别是癌症。
• Cu(II) and Pd(II) complexes of N-(2-hydroxybenzyl)aminopyridines
  作者：Bahattin Yalçın、Perizad A. Fatullayeva、Orhan Büyükgüngör、Başak Koşar、Sülin Taşcıoğlu、Akif I. Israfilov、Zaur D. Ibayev、Ajdar A. Medjidov、Adnan Aydın

  DOI：10.1016/j.poly.2007.03.015

  日期：2007.8

  N-(2-Hydroxybenzyl)aminopyridines (L) react with Cu(II) and Pd(II) ions to form complexes in the compositions Cu(Li)2(CH3COO)(2) center dot nH(2)O (n = 0.14), Pd(L-i)(2)Cl-2 center dot nC(2)H(5)OH (n = 0, 2) and Pd(L-2)(2)Cl-2 center dot 2H(2)O- In the complexes, the ligands are neutral and monodentate which coordinate through pyridinic nitrogen. Crystal data of the complexes obtained from 2-amino pyridine derivative have pointed such a coordinating route and comparison of the spectral data suggests the validity of similar complexation modes of other analog ligands. Cu(II) complex of N-(2-hydroxybenzyl)-2-aminopyridine (L), [Cu(L-1)(2)(CH3COO)(2)] has slightly distorted square planar cis-mononuclear structure which is built by two oxygen atoms of two monodentate carboxylic groups disposed in cis-position and two nitroaen atoms of two pyridine rings. The remaining two oxygen atoms of two carboxylic groups form two Cu and H bridges containing cycles which joint at same four coordinated copper(II) ion. IR and electronic spectral data and the magnetic moments as well as the thermogravimetric analyses also specify on mononuclear octahedric structure of complexes [Cu(L-2)(2)(CH3COO)(2) center dot 2H(2)O] and [Cu(L-3)(2)(CH3COO)(2) center dot 4H(2)O] where L-2 and L-3 are N-(2-hydroxybenzyl)-2- or 3-aminopyridines, respectively. X-ray analysis for [Pd(L-1)(2)Cl-2 center dot 2C(2)H(5)OH] show square planar environment around Pd(II) ion formed by two chlorine atoms in trans position and two nitrogen atoms of pyridine rings. The spectral data indicate structural similarity in the complexes obtained via ligand exchange between PdCl2(PhCN)(2) and 3-amino and 4-aminopyridine derivatives. (c) 2007 Elsevier Ltd. All rights reserved.